Precision Decision Making in Platinum Resistant Ovarian Cancer: Folate Receptor Alpha Expression and Other Biomarkers Into Contemporary Care
Despite advances in ovarian cancer treatment, outcomes for patients with platinum‑resistant disease remains poor, with therapeutic decisions becoming increasingly complex as novel biomarkers and targeted therapies emerge. This 45‑minute case‑based educational program will provide clinicians with practical guidance on integrating folate receptor alpha (FRα) testing into real‑world decision‑making, alongside emerging considerations such as weekly paclitaxel and/or bevacizumab eligibility, PD-L1, HER2 status, and other biologic drivers. Through interactive discussion of patient cases led by two expert faculty, learners will explore how biomarker evaluation, clinical characteristics, and prior therapies influence treatment selection and sequencing, with an emphasis on optimizing outcomes in platinum‑resistant ovarian cancer.
